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Abstract: Osteoporosis in the aging male remains an important yet under-recognized and 
undertreated disease. Current US estimates indicate that over 14 million men have osteoporosis 
or low bone mass, and men suffer approximately 500,000 osteoporotic fractures each year. Men 
experience fewer osteoporotic fractures than women but have higher mortality after fracture. 
Bisphosphonates are potent antiresorptive agents that inhibit osteoclast activity, suppress in vivo 
markers of bone turnover, increase bone mineral density, decrease fractures, and improve survival 
in men with osteoporosis. Intravenous zoledronic acid may be a preferable alternative to oral 
bisphosphonate therapy in patients with cognitive dysfunction, the inability to sit upright, or 
significant gastrointestinal pathology. Zoledronic acid (Reclast) is approved in the US as an 
annual 5 mg intravenous infusion to treat osteoporosis in men. The zoledronic acid (Zometa) 
4 mg intravenous dose has been studied in the prevention of bone loss associated with androgen 
deprivation therapy.
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Osteoporosis in the aging male
Osteoporosis is a systemic skeletal disorder characterized by low bone mass and 
microarchitectural deterioration of bone tissue, with a consequent increase in bone 
fragility and susceptibility to fracture.1 The National Osteoporosis Foundation (NOF) 
estimates that over 14 million American men had osteoporosis or low bone mass in 
2002.2 One in four men older than 60 years of age will experience a fracture,3 yet 
age-related bone loss in men remains under-recognized and undertreated.
Sixteen percent of men older than 50 and 35% men older than 85 fall each year.4 
Hip fractures in men increase mortality by fourfold in the first three months after 
fracture,5 and one-year mortality reaches 20%.6 Epidemiologic surveys consistently 
show higher mortality in men than women of similar ages after fracture.7 Among 
survivors of hip fracture, more than 1 in 4 becomes disabled in the following year,8 
and nearly 1 in 5 will require long-term nursing home care.9 Care for patients after hip 
fracture is expensive to society. In the US, direct costs for patients with osteoporotic 
fractures is estimated at up to $18 billion/year in 2002 dollars. White men account 
for 18% of these costs, or $3.2 billion annually.10 Vertebral fractures also increase 
long-term mortality,3,7,11 cause persistent back pain, deformity, functional decline, and 
diminished quality of life.
Importantly, the prevalence of osteoporosis and osteoporotic fractures are expected 
to rise as men live longer. The NOF predicts that there will be 20.5 million American Clinical Interventions in Aging 2009:4 290
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men with osteoporosis or low bone mass by 2020.2 By 2025, 
annual costs for osteoporosis-related fractures is expected to 
be $25.3 billion.2
Identifying men at high risk  
for osteoporotic fracture
Previous fracture is the strongest predictor of any future 
fracture. The Osteoporotic Fractures in Men (MrOS) Study12 
followed 5995 men aged 65 and older and showed that men 
with a history of fracture after 50 years had a twofold increased 
risk of nonvertebral fracture compared to men without prior 
fracture. A second important predictor of fracture is advancing 
age. The Dubbo Study showed that, compared to men aged 
70–74 years, men older than 80 years had 28 times as many 
vertebral fractures, nine times as many hip fractures, and nearly 
five times as many overall fractures.13 Third, bone mineral 
density (BMD) predicts fracture risk. The use of BMD by dual 
energy X-ray absorptiometry (DEXA) to predict fracture risk is 
comparable to the use of blood pressure to predict stroke and is 
substantially better than using serum cholesterol to predict the 
risk of myocardial infarction. The MrOS investigators12 also 
found that tricyclic antidepressant use (hazard ratio [HR] 2.36), 
the inability to complete a narrow walk trial (HR 1.70), falls 
in previous year (HR 1.59), and depressed mood (HR 1.72) 
all increased fracture risk independent of BMD.
Bone quality indicators such as cortical thickness, micro-
architecture, turnover, porosity, damage accumulation, and 
the rate and quality of mineralization are other important 
predictors of fracture, yet they are difficult to incorporate 
into clinical practice.14 Compared to women, men have bones 
with larger cross-sectional areas, and as men age they tend to 
preserve trabecular number. Apart from bone density, both 
of these factors are thought to ameliorate fracture risk.
In addition to age-related bone loss, osteoporosis in men 
is frequently secondary to other comorbidities such as gluco-
corticoid use, hypogonadism, vitamin D deficiency, cigarette 
smoking, heavy alcohol intake, immobility, or inadequate 
dietary calcium intake. Studies among ambulatory men with 
osteoporosis indicate that 30%–64% have at least one identifi-
able risk factor.15,16 The World Health Organization (WHO) 
has developed the FRAXTM fracture risk assessment tool, 
a group of country- and ethnicity-specific risk calculators 
which allow an estimate of fracture risk based on historical 
and exam findings.17
Treatment strategies
Traditional nonpharmacologic therapies include treatments 
intended to increase bone mineral density, prevent falls, 
and prevent fractures with falls. Several recent papers have 
reviewed the literature on fall prevention, hip protectors, 
and calcium and vitamin D supplementation in men.14,18,19 
Weight bearing exercise can prevent falls20 and increase 
BMD.21 Inadequate dietary calcium and vitamin D intake 
are risk factors for osteoporosis. The NOF recommends that 
individuals 50 years old and older consume 1200 mg calcium 
and 800–1000 IU vitamin D daily. Several studies of calcium 
and vitamin D supplementation have shown increased 
BMD, decreased fracture risk,22–24 and even decreased 
mortality23 irrespective of baseline 25-hydroxyvitamin 
D levels. However, another large randomized controlled 
trial of calcium and vitamin D in secondary prevention of 
osteoporotic fractures showed no benefit.25
The NOF recommends drug treatment for men aged 50 and 
older with prior hip or vertebral fracture, with osteoporosis 
(T-score  -2.5 at the femoral neck or spine), or with osteo-
penia (T-score between -1.0 and -2.5 at the femoral neck or 
spine) and an absolute 10-year risk of hip fracture 3% or 
10-year risk of a major osteoporosis-related fracture 20% 
based on the FRAX calculation.26 Drugs for the treatment of 
osteoporosis can be classified into antiresorptive or anabolic 
agents. Antiresorptive agents, or drugs that inhibit osteoclast 
action, include most of the commonly used therapies in men 
such as calcitonin, testosterone, and bisphosphonates.
Calcitonin
Trovas and colleagues27 randomized 28 osteoporotic men 
to receive daily intranasal calcitonin 200 IU or placebo. 
At 12 months, the treated group had significantly suppressed 
markers of bone turnover and greater BMD at the lumbar 
spine but not hip. Toth and colleagues28 studied 71 men 
with idiopathic osteoporosis but no prior fracture. In these 
men, intranasal calcitonin daily during alternate months for 
18 months significantly increased BMD at the spine and hip 
and decreased vertebral fractures.
Calcitonin is not approved in the US for the treatment of 
male osteoporosis.
Testosterone
Studies have consistently shown that testosterone replace-
ment improves BMD in hypogonadal men.29–32 Snyder 
and colleagues31 randomized 108 men aged over 65 years 
without osteoporosis to daily testosterone patch or 
placebo. They found no treatment effect on BMD in the 
group as a whole or in men with baseline testosterone 
level 400 ng/dL. Anderson and colleagues33 studied intra-
muscular testosterone injections every two weeks in men Clinical Interventions in Aging 2009:4 291
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with osteoporosis and prior vertebral fracture. In this 
population, the authors found that testosterone therapy 
suppressed markers of  bone turnover and significantly 
increased lumbar spine BMD.
No studies have assessed the effect of testosterone 
replacement on fracture risk, and testosterone is not approved 
in the US for the treatment of osteoporosis.
Teriparatide
Teriparatide (1–34 PTH), stimulates bone formation. 
Teriparatide has been shown to raise BMD in men at the 
hip and spine more than alendronate alone,34,35 and it reduces 
vertebral fractures by 90%.35
Teriparatide is approved by the US FDA for treatment of 
osteoporosis in men considered at high risk for fracture.
Bisphosphonates
Bisphosphonates are synthetic pyrophosphate analogues 
with a P-C-P backbone that is resistant to hydrolysis and 
two phosphate groups that bind hydroxyapatite with high 
affinity. The central carbon binds the R1 side chain, often a 
hydroxyl group, which binds calcium and allows for more 
stable interaction with the bone matrix.36 The longer R2 side 
chain gives each bisphosphonate its characteristic properties 
and potency. Bisphosphonates can be classified based on the 
presence or absence of a nitrogen atom in the R2 side chain. 
The nitrogen-containing bisphosphonates (alendronate, 
risedronate, ibandronate, and zoledronic acid) are more 
potent inhibitors of osteoclast action.37
Mechanism of action
Bisphosphonates are poorly absorbed through the gut, with 
less than 1% bioavailability after oral administration.38 The 
kidneys excrete approximately 50% of the drug unchanged.39 
The remaining bisphosphonates bind hydroxyapatite crys-
tals on the bone surface with high affinity, where they are 
internalized by and accumulate in osteoclasts.
Within the osteoclast, the nonnitrogen containing 
bisphosphonates (etidronate, tiludronate) are incorporated 
into adenosine triphosphate (ATP). These nascent nonhy-
drolyzable ATP analogs are toxic to osteoclasts, leading 
to mitochondrial inhibition and osteoclast apoptosis.40 The 
nitrogen-containing bisphosphonates inhibit the enzyme 
farnesyl pyrophosphate synthase (FPPS) in the HMG-
CoA reductase pathway leading to cholesterol synthesis. 
In addition to cholesterol synthesis, this pathway produces 
the intermediate metabolites farnesol and gerinylgeranol 
that are necessary for protein prenylation. Prenylation is 
the posttranslational attachment of  hydrophobic prenyl 
groups to cytoplasmic proteins to allow binding to the cell 
membrane.40 Such modification allows the Ras superfamily 
of GTPases to exert changes in cytoskeletal function that 
produce the characteristic osteoclast ruffled border and 
allow osteoclast attachment to bone.41 Biopsies of alendro-
nate-treated bone show greater numbers of osteoclasts and 
abnormal giant, hypernucleated osteoclasts detached from 
bone. The number of osteoclasts increased with cumula-
tive dose of alendronate, suggesting that the drug may 
prolong osteoclast survival.42 Bisphosphonate potency, 
the ability to inhibit bone resorption in vivo, is directly 
related to drug ability to inhibit FPPS in vitro.37 Nitrogen-
containing bisphosphonates also inhibit osteoclast precursor 
differentiation and inhibit osteoblast-mediated osteoclast 
activation.38
Evidence of benefit
Pamidronate
Several randomized controlled trials of pamidronate for the 
treatment of osteoporosis include men. Ryan and colleagues43 
randomized 122 subjects with prior vertebral fracture to oral 
pamidronate 300 mg/day (group A) for four weeks every 
16 weeks, 150 mg/day (group B) for four weeks every eight 
weeks or placebo (group C). At 2 years, the authors reported 
significant reductions in serum osteocalcin (29% group A and 
33% group B) and urinary deoxypyridinoline (16% group A, 
21% group B, p  0.01 for all comparisons to placebo). They 
found significant increases in BMD at the spine, hip, and 
total body (See Table 2).
Brumsen and colleagues44 randomized 101 subjects with 
prior vertebral fracture to oral pamidronate 150 mg/day or 
placebo. At three years, the investigators found significant 
reductions in urinary hydroxyproline and serum alkaline 
phosphatase and significant increases in BMD at the lumbar 
spine (See Table 2). Men and women had similar increase in 
BMD in response to pamidronate. There were significantly 
fewer morphometric vertebral fractures (ARR 22%) in the 
pamidronate group, and the number needed to treat (NNT) 
Table 1 relative potency of bisphosphonates37
Drug Relative potency
Pamidronate (Aredia) 1
Alendronate (Fosamax) 4
Ibandronate (Boniva) 10
risedronate (Actonel) 20
Zoledronic acid (Zometa, reclast) 67Clinical Interventions in Aging 2009:4 292
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with pamidronate for three years to prevent one vertebral 
fracture was 5. Six subjects in the placebo group and three 
pamidronate-treated subjects experienced symptomatic 
vertebral fractures. Three subjects in the placebo group and 
one pamidronate-treated subject experienced nonvertebral 
fractures (ARR 4%). At the end of three years, 53 of the 
study subjects agreed to participate in an open-label two year 
extension of the trial. There were equal numbers from the 
pamidronate and placebo groups, and all subjects received 
oral pamidronate 150 mg/day. With pamidronate treatment, 
the differences in urinary hydroxyproline and serum alkaline 
phosphatase between the initial study groups disappeared. 
The BMD of the prior placebo group increased to greater 
extent compared to the prior treatment group such that, at 
the end of an additional two years there was no significant 
difference in femoral neck BMD between the groups. The 
subjects who received pamidronate for five years continued 
to have a small yet significant greater increase in lumbar 
spine BMD compared to those subjects who had initially 
received placebo.
Boutsen and colleagues45 studied 27 subjects who required 
initiation of long-term glucocorticoid therapy at a dose of at 
least 10 mg/day prednisolone for polymyalgia rheumatica 
(16), inflammatory bowel disease (4), temporal arteritis (3), 
and rheumatoid arthritis (2). The subjects were randomized 
to receive a single dose IV pamidronate 90 mg at the start 
of glucocorticoid therapy (group A); IV pamidronate 90 mg 
once followed by 30 mg IV pamidronate every three months 
(group B); and control (group C). Both treatment groups 
experienced significant decreases in bone-specific alkaline 
phosphatase, osteocalcin, and C-telopeptide at three months. 
At 12 months, however, all bone markers of the once-treated 
group had risen again and only group B observed a sustained 
decrease in bone resorption. At six and 12 months, there was 
significantly greater BMD at the lumbar spine, femoral neck, 
and total hip in both treatment groups compared to control 
(see Table 2). There were no fractures recorded during the 
12 month study.
Pamidronate is not approved in the US for the treatment 
of osteoporosis in men or women.
Alendronate
Alendronate was the first bisphosphonate to be extensively 
studied in men. In a study by Ho and colleagues,46 80 sub-
jects with either primary or secondary osteoporosis and 
prior vertebral fracture received alendronate 10 mg daily. 
The investigators also followed 43 matched controls. Over 
12 months follow-up, the investigators found significantly 
Table 2 Studies of bisphosphonates for the treatment of osteoporosis in men 
Citation Drug Study 
design
N Follow-up 
(mo)
Men Avg age Fracture RRR D % increase BMD
Any Vert NV H FN LS
ryan et al43 pamidronate rCT 122 24 9% 65.2           3.5%–5.0%
Brumsen et al44 pamidronate rCT 101 36 23% 64.5   67% 67%   NS 5.3%
Boutsen et al45 pamidronate rCT 27 12 44% 57       3.2%–4.8% 4.3% 6.3%–6.9%
Ho et al46 alendronate PU 123 12 57% 64.2         NS 6.4%–7.0%
Orwoll et al47 alendronate rCT 241 24 100% 63   86% NS 2.6% 2.6% 5.3%
ringe et al48 alendronate rCT 134 36 100% 53   57% NS   3.5% 8.0%
ringe et al50 risedronate rCT 316 12 100% 56.9   60% NS 2.3% 1.6% 3.7%
Boonen et al51 risedronate rCT 284 24 100% 60.7 NS         4.6%
reid et al52 risedronate rCT 184 12 100% 57.7   82%        
Sato et al53 risedronate rCT 280 18 100% 76.3     75%      
Kanaji et al56 risedronate rCT 23 12 100% 63–87   56%        
Lamy et al55 ibandronate PU 14 24 100% 57       0.9% 1.4% 6.7%
ringe et al66 ibandronate rCT 115 36 46% 64   62% NS   3.3% 10.7%
HOrIZON-rFT69 zoledronic acid rCT 2127 36 24% 74.5 35% 46% 27% 6.4% 4.3%  
Poole et al72 zoledronic acid rCT 27 12 78% 69.8       5.5% NS  
Bolland et al75 zoledronic acid rCT 43 24 100% 49.1       4.6%   6.3%
Brown et al79 zoledronic acid PU 66 36 100% 42       4.3%   4.8%
Abbreviations: RCT, prospective, randomized controlled trial; PU, prospective, unrandomized trial; vert, vertebral; NV, nonvertebral; NS, not significant; H, total hip; FN, femoral 
neck; LS, lumbar spine. All comparisons are statistically significant with p  0.05.Clinical Interventions in Aging 2009:4 293
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improved BMD at the lumbar spine and femoral trochanter 
but not femoral neck (See Table 2). Results were similar for 
women and men.
Orwoll and colleagues47 randomized 241 men with 
osteoporosis to 10 mg daily alendronate or placebo. After 
two years of treatment, the authors observed a significant 
59% decrease in urinary N-telopeptide of type I collagen 
and 38% decrease in bone-specific alkaline phosphatase 
in the alendronate group. In the alendronate-treated group, 
bone mineral density at 24 months increased significantly 
at the lumbar spine, total hip and femoral neck compared 
to placebo. Quantitative analysis of spine radiographs 
revealed significantly fewer vertebral fractures in the 
alendronate group (aldosterone–renin ratio [ARR] 6.3%) 
but no significant difference in nonvertebral fractures (See 
Table 2).
These findings were confirmed by Ringe and colleagues48 
in an open label study of 134 men with osteoporosis random-
ized to 10 mg daily alendronate or the vitamin D analog 
alfacalcidol 1 µg daily. With three years follow-up, they 
observed significantly greater increases in BMD at the lumbar 
spine and femoral neck in the alendronate-treated group. The 
alendronate group had significantly fewer vertebral fractures 
(ARR 13.9%, p = 0.04) and no difference in nonvertebral 
fractures (See Table 2).
A meta-analysis of the alendronate trials including 
375 men49 concluded that alendronate treatment significantly 
decreases the risk of vertebral fractures (odds ratio [OR] 0.36) 
in men with osteoporosis. There were not sufficient data to 
confirm a significant decrease in nonvertebral fractures.
Alendronate is approved in the US for the treatment of 
osteoporosis in men.
risedronate
Ringe and colleagues50 studied risedronate in 316 men 
with primary or secondary osteoporosis. Over half of those 
enrolled had a vertebral fracture prior to the start of the 
study. Subjects were randomized to risedronate 5 mg daily 
or control, and all received calcium and vitamin D supple-
mentation. At 12 months, there was a significantly greater 
improvement in BMD at the lumbar spine, total hip, and 
femoral neck. At one year, the treated subjects experienced 
fewer vertebral fractures (ARR 7.6%, p = 0.028), a nonsig-
nificant 42% decrease in nonvertebral fractures, and signifi-
cantly less back pain than the control group (See Table 2).
Boonen and colleagues51 randomized 284 men with 
osteoporosis but without prior fracture to weekly risedronate 
35 mg or placebo in 2:1 ratio. The risedronate-treated group 
had significant reductions in the bone turnover markers 
c-telopeptide, n-telopeptide, and bone-specific alkaline 
phosphatase at three months, and these effects persisted 
throughout the two-year study period. The treatment group 
also experienced significantly greater increases in BMD at the 
lumbar spine by three months and at the total hip and femoral 
neck by six months (see Table 2). These treatment differ-
ences increased throughout the study. The authors noted a 
nonsignificant trend toward overall fracture reduction, though 
the study was not powered to detect a difference.
Reid and colleagues52 studied 184 men enrolled in 
two RCT receiving daily risedronate 2.5 mg, risedronate 
5 mg, or placebo for the prevention or treatment of 
glucocorticoid-induced osteoporosis (GIO). Prior to 
enrollment, the subjects had received either 3 months 
(prevention study) or 6 months (treatment study) chronic 
O
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Figure 1 Generic bisphosphonate structure.
Figure 2 Comparison of structures of different bisphosphonates.
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oral glucocorticoid therapy of at least 7.5 mg/day prednisone 
or equivalent, most commonly for rheumatoid arthritis, 
lung disease, and polymyalgia rheumatica. At one year, 
the subjects treated with risedronate 5 mg/day experienced 
61% decrease in urinary n-telopeptide and 20% reduction in 
bone-specific alkaline phosphatase. The GIO treatment study 
group treated with risedronate 5 mg experienced significant 
increases in BMD at the lumbar spine and femoral neck 
compared to baseline. In the GIO prevention study, risedro-
nate 5 mg/day prevented the significant loss in BMD at the 
hip and lumbar spine seen in the placebo group. The authors 
reported that risedronate 2.5 mg/day produced similar yet 
smaller effects on BMD. When both risedronate treatment 
arms from both studies were combined, the authors found a 
19% ARR in morphometric vertebral fractures at one year. 
However, fracture data were reported for only 96 of the 
184 enrolled subjects.
Prior stroke is a risk factor for fracture, through 
immobility decreasing bone mineral density and by gait 
instability increasing risk for falls. Sato and colleagues53 
studied 280 men 65 years or older after hemiplegic stroke. 
The subjects were randomized to risedronate 2.5 mg 
daily or placebo and followed for 18 months. Urinary 
deoxypyridinoline concentration decreased significantly 
compared to baseline and compared to placebo within the 
first six months of risedronate treatment and remained 
stable thereafter. The authors assessed BMD at the second 
metacarpal bones on both hemiplegic and unaffected sides. 
On the hemiplegic side, metacarpal BMD increased 2.5% in 
the risedronate-treated and decreased 3.5% in the untreated 
group. On the unaffected side, metacarpal BMD increased 
3.3% in the treated and decreased 2.0% in the unaffected 
side. Differences between groups were highly significant 
(p  0.001). During the study period, 87 men fell a total 
of 547 times. The risedronate group experienced fewer hip 
fractures (ARR 5.7%) and overall fractures (ARR 8.6%) 
though asymptomatic vertebral fractures were not assessed, 
and no vertebral fractures were reported (See Table 2). The 
NNT to prevent hip fracture was 16.
Hypogonadism affects approximately 50% men with 
leprosy due to gonadal atrophy from testicular Mycobacterium 
leprae infection.54 As a result, osteoporosis is very common 
in men with leprosy. Among 197 men with leprosy residing 
at a national leprosarium, Ishikawa and colleagues55 found 
the prevalence of osteoporosis to be 33% in men 50–59 aged 
years and 75% in men aged at least 80 years. Kanaji and 
colleagues56 followed 23 elderly men with leprosy random-
ized to 2.5 mg daily oral risedronate or placebo and found 
a significant reduction in urinary N-telopeptides and a sig-
nificant increase in lumbar spine BMD at six and 12 months 
(See Table 2). Though there was a low incidence of vertebral 
fractures observed, the treatment group experienced fewer 
(ARR 1.06%).
Risedronate is approved in the US for the treatment of 
osteoporosis in men.
Limitations of oral therapy
Because of their relative ease of use and low cost of 
generic alendronate, oral bisphosphonates have become 
mainstays of osteoporosis pharamacotherapy. Yet oral 
dosing is poorly absorbed, may worsen gastrointes-
tinal toxicities, and side effects can decrease patient 
compliance. Esophageal injury may occur in patients 
on oral bisphosphonates, though randomized trials have 
failed to show significant association. Even in patients 
who strictly adhere to recommended use directions, case 
reports have shown oral alendronate has the potential 
to cause erosive esophagitis, esophageal or gastric 
ulcers and esophageal strictures.57 Recent reports of oral 
bisphosphonate-associated esophageal carcinoma have 
emerged.58 A meta-analysis of 76 randomized controlled 
trials of osteoporosis drug trials found that esophageal 
ulcerations and complications such as perforation and 
hemorrhage were reported in trials of all bisphosphonates 
except zoledronic acid.59 Other gastrointestinal symptoms 
related to oral bisphosphonates include pyrosis, dyspepsia, 
abdominal pain, nausea, and vomiting.
Long-term compliance with oral bisphosphonate therapy 
is low, and patients most commonly cite adverse drug effects 
as the reason for stopping therapy.60,61 One systematic review 
of seven observational studies of bisphosphonate compliance 
as measured by patient surveys indicates that the discon-
tinuation rate at one year of daily dosing ranged 19%–29%. 
In the study that included men, the rate was 22%. However, 
when compliance is measured by administrative data, the 
discontinuation rate was 68% for daily dosing and 56% for 
weekly dosing. Moreover, 76% patients had at least some 
interruption in bisphosphonate therapy during the first year 
of therapy.61 The costs of bisphosphonate noncompliance 
are high. Patients who are less than 66% compliant with 
osteoporosis medications have significantly lower increases 
in BMD.62 In an analysis of insurance claims databases 
involving 35,537 women prescribed bisphosphonates, 
only 43% women filled at least 80% of their prescriptions. 
However, the medication-compliant women had 37% fewer 
hip fractures at 24 months.63Clinical Interventions in Aging 2009:4 295
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Oral bisphosphonates are poorly absorbed, and dietary 
calcium, calcium supplements, and antacids further impede 
absorption. In order to optimize bioavailability, the patient 
should take the medication apart from food and all other 
medications for at least two hours before and 30 minutes after 
the dose. In order to minimize gastrointestinal side effects, 
the patient should take the medication with 6–8 ounces of 
water and remain upright for 30 minutes thereafter. In a 
review of three observational trials of adherence to dosing 
instructions, up to 52% patients did not comply with at least 
one instruction.61 In one of the studies, 26% patients were 
not taking risedronate correctly and among these patients 
28% experienced adverse effects.64
Factors associated with poorer bisphosphonate compliance 
include older age, male gender, nonwhite race, and greater 
number of comorbid conditions and nonosteoporosis 
medications. Compliance is improved with weekly vs 
daily dosing, and residence in a nursing home.61,65 Though 
not reported in these trials, compliance with the complex 
administration instructions is very likely also limited by 
cognitive dysfunction and physical debility.
Ibandronate
In an uncontrolled open label pilot, Lamy and colleagues66 
enrolled 14 men with primary osteoporosis and either a 
prior osteoporotic fracture or a BMD at least 1.5 standard 
deviations below the age-matched mean. Subjects received 
2 mg IV ibandronate every three months. At two years, 
the authors noted significant reductions in osteocalcin and 
β-crosslaps assay for degradation products of type I collagen. 
During the two years of treatment, they showed significant 
increases in BMD at the lumbar spine, femoral neck, and 
total hip (See Table 2).
Another as yet unpublished trial of 168 men randomized 
to monthly oral ibandronate 150 mg or placebo has the 
primary outcome of change in lumbar spine BMD. One 
year follow-up has been completed, and data will soon be 
presented (personal communication).
Ringe and colleagues67 studied 115 subjects with 
established glucocorticoid induced osteoporosis. The subjects 
required chronic prednisone use of at least 7.5 mg/day for 
other systemic illnesses, most commonly COPD, rheumatoid 
arthritis, or polymyalgia rheumatica. Subjects were 
randomized to 2 mg intravenous (IV) ibandronate every 
three months vs. daily oral alfacalcidol. Ibandronate-
treated subjects experienced significantly greater increases 
in BMD at the spine and femoral neck, and improvements 
were progressive throughout the 36-month study period. 
The ibandronate group had less lower back pain and less 
height loss. Though not powered to detect fracture difference, 
the study did show significantly fewer vertebral fractures in 
the ibandronate group (relative risk reduction [RRR] 62%) 
and a nonsignificant trend toward fewer nonvertebral frac-
tures (See Table 2).
Ibandronate is not approved in the US for the treatment 
of osteoporosis in men.
Zoledronic acid
Currently available IV nitrogen-containing bisphosphonates 
include pamidronate, ibandronate, and zoledronic acid. 
Zoledronic acid is the only IV bisphosphonate FDA-approved 
for the treatment of osteoporosis in men. It has the highest 
binding affinity to hydroxyapatite and the highest skeletal 
uptake68 and is the most potent osteoclast inhibitor. 
Zoledronic acid is the only bisphosphonate with an indica-
tion for annual use.
Evidence of benefit
The HORIZON investigators studied zoledronic acid in 
secondary prevention of osteoporotic fractures.69 They 
randomized 2127 subjects (24% men) within 90 days of 
surgical repair of a hip fracture to receive 5 mg annual 
IV zoledronic acid or placebo with first dose given within 
90 days of hip fracture repair. At 36 months, the treated group 
had significantly increased bone density at the total hip and 
femoral neck compared to the placebo group. Over 1.9 years 
median follow-up, they observed significant decreases in 
any new fracture (139 vs 92, ARR 5.3%), clinical vertebral 
fracture (39 vs 21, ARR 2.1%), nonvertebral fracture (107 vs 
79, ARR 3.1%), and recurrent hip fracture (33 vs 23, ARR 
1.5%; see Table 2). Further, in this population at high risk 
for deadly recurrent fractures, the zoledronic acid-treated 
group experienced a survival advantage (RRR 28%, ARR 
3.7%).69 Men enjoyed a greater survival benefit than women 
(overall mortality ARR 6.4%) and a marked reduction in 
cardiac-related deaths (RRR 62%, RRR 4.8%).70
Zoledronic acid has been approved in the US for treatment 
of osteoporosis in men on the basis of an as yet unpublished 
trial.71 The study randomized 302 hypogonadal men to annual 
5 mg IV zoledronic acid or weekly 70 mg oral alendronate. 
At two years, the zoledronic acid group had 6.1% increase in 
lumbar spine BMD compared to 6.2% increase in alendronate 
group. The all-cause mortality and serious adverse events 
were similar between treatment groups.
Poole and colleagues72 randomized 27 hemiplegic 
subjects within seven weeks after stroke zoledronic acid 4 mg Clinical Interventions in Aging 2009:4 296
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or placebo. The authors showed that treatment prevented 
significant bone loss at the hip. Without treatment, at one 
year the mean BMD of the total hip decreased 5.5% on the 
affected (hemiplegic) side and by 2.7% in the unaffected 
hip. With treatment, the mean BMD remained stable on the 
hemiplegic side and increased by 1% at the unaffected hip 
(see Table 2). 72% subjects fell, but there were no fractures 
during the study period.
Human immunodeficiency virus (HIV) infection and 
antiretroviral therapy are associated with low bone density and 
osteoporosis. Brown and colleagues73 found that HIV-infected 
patients were 3.7 times as likely to have osteoporosis as 
uninfected individuals. Triant and colleagues74 reported that 
HIV-infected men and women have a significantly higher 
prevalence of hip, vertebral, and wrist fractures. Bolland 
and colleagues75 studied zoledronic acid in 43 HIV+ men 
with decreased bone mineral density receiving antiretroviral 
therapy. The men were randomized to 4 mg IV annual 
zoledronic acid or placebo. Urinary N-telopeptide decreased 
by 61%, and serum total alkaline phosphatase decreased 
by 21% from baseline by three months in the zoledronic 
acid-treated group. These values were significantly less than 
the untreated group, and the levels did not further decrease 
over the remaining two years in the study. In the zoledronic 
acid group, BMD increased significantly at the lumbar spine 
and total hip over the control group (see Table 2).
Studies confirm both clinical efficacy69,72,75 of annual 
zoledronic acid dosing and noninferiority compared to 
more frequent dosing,76 but it is not yet known how long a 
single dose of zoledronic acid can suppress bone turnover. 
Borba and colleagues77 showed persistent suppression of 
C-telopeptide and bone-specific alkaline phosphatase and 
persistent increase in bone mineral density at the lumbar 
spine and total hip at 18 months after a single dose of zole-
dronic acid. In an extension of a previous trial, Bolland and 
colleagues78 showed persistence of drug effect in men at 
two years after a second annual dose of zoledronic acid in 
suppressing markers of bone turnover and increasing bone 
mineral density. Brown and colleagues79 studied 66 subjects 
with osteopenia after curative cancer treatment. All subjects 
received a single dose 4 mg zoledronic acid and were 
followed for 36 months. Data were reported for men and 
women separately, and both showed durable decreases in 
urinary NTx/Cr and increases in BMD at the spine and hip 
after at 36 months after a single zoledronic acid dose. Less 
frequent dosing regimens offer potential advantages such as 
reduced toxicity, greater convenience, improved compliance, 
and reduced cost. Though markers of bone turnover remain 
suppressed for more than one year, it is not known whether 
dosing zoledronic acid less than annually is as effective in 
terms of reduction in fracture risk.
Comparing therapies for osteoporosis
Few studies have made direct comparison of osteoporosis 
therapies in men. In theory, drugs such as teriparatide that 
stimulate bone formation may complement bisphosphonates 
(which inhibit osteoclast action) and provide even greater 
increases in BMD. Finkelstein and colleagues34,80 randomized 
83 men with low bone mass to receive alendronate, 
teriparatide, or both daily. Subjects receiving alendronate 
started treatment at the beginning of the study, and subjects 
receiving teriparatide started at month 6. Sixty-three men 
completed the study. At 30 months, the authors found that 
teriparatide increased BMD at the lumbar spine and femoral 
neck significantly more than combination therapy, and com-
bination therapy increased BMD at the lumbar spine and 
femoral neck significantly more than alendronate alone.34 
The authors went on to show that marker of bone turnover 
such as serum N-telopeptide (NTX), osteocalcin, and 
amino-terminal propeptide of type 1 procollagen increased 
markedly upon starting teriparatide monotherapy and then 
declined toward baseline. With alendronate monotherapy, 
the markers of bone turnover decreased and remained stable. 
Combination therapy led to an initial decline in bone markers 
on alendronate alone followed by a rebound with teriparatide 
so that levels returned to baseline or above. Alendronate pre-
treatment blunted the treatment effect of teriparatide,80 and 
the authors conclude that alendronate impairs the ability of 
teriparatide to increase bone turnover or increase the BMD 
at the lumbar spine and the femoral neck in men.
Welch and colleagues81 retrospectively studied 149 men 
treated with testosterone, alendronate, or both for at least one 
year. Men in the testosterone group were referred for treat-
ment of hypogonadism, and men in the alendronate group 
were referred for treatment of osteoporosis. Yet at baseline, 
the groups were similar in terms of age, weight, body mass 
index, and BMD at the lumbar spine and total hip. Compared 
with the baseline values, lumbar spine BMD increased 
significantly by 2.1% in the testosterone group, 2.6% in 
the alendronate group, and 2.5% in the group receiving 
combination therapy. There were no significant differences 
in BMD at the lumbar spine or total hip between groups, sug-
gesting that the combination of testosterone and alendronate 
does not appear to be superior to either drug used alone.
A recently conducted, unpublished trial at our institution 
directly compares alendronate and zoledronic acid in Clinical Interventions in Aging 2009:4 297
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the treatment of male osteoporosis. The investigators 
retrospectively reviewed the charts of 64 men: 26 received 
annual IV zoledronic acid 4 mg and 38 received weekly oral 
alendronate 70 mg. At one year, they found no differences in 
BMD at the lumbar spine or femoral neck between groups 
(personal communication).
Bisphosphonate use in bone loss  
due to androgen deprivation
Prostate cancer becomes increasingly common as men 
age, and androgen deprivation therapy (ADT) for prostate 
cancer places men at uniquely high risk for osteoporosis and 
fracture. ADT, which may include orchiectomy or GnRH 
agonist therapy, markedly reduces circulating testosterone 
to prepubertal levels. In one prospective cohort study of 
152 men with nonmetastatic prostate cancer including 30 on 
acute ADT  6 months and 50 on chronic ADT  6 months, 
Greenspan and colleagues82 found that men starting ADT 
experienced significant reductions in bone mineral density 
(2.5% total hip, 4.0% spine) by 12 months follow-up. When 
compared to healthy age-matched controls and to patients 
with prostate cancer but not on ADT, the acute ADT had five- 
to tenfold increased bone density loss at multiple skeletal 
sites. When compared to men on chronic ADT, it appeared 
that the greatest bone loss occurred in the first 12 months of 
ADT. Shananian and colleagues83 measured fracture rates on 
50,613 men with the diagnosis of prostate cancer. Among the 
men that survived five years after diagnosis, they found that 
19.4% men on ADT experienced a fracture, as compared to 
12.6% those not receiving ADT (p  0.001). Furthermore, 
fractures at every site, fractures requiring hospitalization, and 
diagnosis of osteoporosis were all significantly increased in 
patients receiving ADT.
Smith and colleagues84 studied 47 men with advanced 
or recurrent nonmetastatic prostate cancer. The authors 
randomized the subjects to receive pamidronate 60 mg 
IV every 12 weeks plus leuprolide or leuprolide alone. 
All measured biomarkers of bone turnover; osteocalcin, 
bone-specific alkaline phosphatase, urinary deoxypyridino-
line, and urinary N-telopeptide were significantly reduced 
in the pamidronate group. Treatment with pamidronate 
prevented the significant reductions in BMD experienced by 
the leuprolide-only group. They reported an absolute differ-
ence between groups in BMD at the lumbar spine and total 
hip, but there was no change in either group at the femoral 
neck (see Table 3).
Greenspan and colleagues85 studied 112 men with non-
metastatic prostate cancer receiving ADT in a partial-crossover 
design. Subjects were randomly assigned to receive alendro-
nate 70 mg weekly or placebo at enrollment. At 12 months, 
all subjects in the placebo group crossed over to the alendro-
nate group, and subjects in the alendronate group were re-
randomized to continue alendronate or placebo. At two years, 
the subjects randomized to alendronate treatment both times 
had the greatest decrease in N-telopeptide, C-telopeptide, type 
1 procollagen, and bone-specific alkaline phosphatase. The 
alendronate-alendronate group also had the highest BMD at 
the lumbar spine, total hip, femoral neck, and distal 1/3 radius. 
Fractures were not studied. The investigators found that a sec-
ond year of alendronate resulted in continued improvements 
in bone density and decreases in bone markers.
Delay in alendronate initiation (as in the placebo–
alendronate group) resulted in lower bone density and 
decreased suppression of bone markers compared to early 
treatment.85 Discontinuation of alendronate (in the alen-
dronate–placebo group) resulted in increases in markers 
of bone turnover and significantly decreased BMD at all 
skeletal sites compared to the alendronate–alendronate arm. 
The authors also performed post-hoc analysis of changes 
in BMD depending on length of ADT prior to alendronate 
treatment. They found that men who received ADT for less 
than 36 months experienced significantly greater increases 
Table 3 Trials in prostate cancer with ADT
 Citation Drug Study 
design
 N  Duration 
(mo)
Avg 
age
D% increase BMD
H FN LS
Smith et al84 pamidronate rCT 47 48 wk 67 2.0% NS 3.8%
Greenspan et al85 alendronate rCT 112 12 71.4      
ryan et al86 zoledronic acid rCT 120 12 72 3.8% 3.6% 6.7%
Smith et al87 zoledronic acid rCT 106 12 70.7 3.9% 3.3% 7.8%
Michaelson et al88 zoledronic acid rCT 40 12 65.5 2.6% 2.1% 7.1%
ryan et al89 zoledronic acid rCT 42 12 65   4.2% 7.1%Clinical Interventions in Aging 2009:4 298
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in BMD on alendronate than men who received ADT for 36 
months or more.
Ryan and colleagues86 studied 120 men with nonmetastatic 
prostate cancer on ADT for 12 months or less prior to 
enrollment. Subjects were randomized to zoledronic acid 4 mg 
IV every three months or placebo and stratified by duration 
of ADT (less than six months or 6–12 months). Treated 
subjects had significant reductions in urinary N-telopeptide 
and serum bone-specific alkaline phosphatase compared to 
the placebo group and significant improvements in BMD at 
one year at the femoral neck, total hip, and lumbar spine (see 
Table 3). The results were not differentiated based on duration 
of ADT. Taken together, these studies85,86 support initiation 
of bisphosphonates within one year of ADT and continued 
treatment for greater than one year in men on ADT.
Smith and colleagues87 studied zoledronic acid in 
106 men with nonmetastatic prostate cancer beginning ADT. 
Subjects were randomized to zoledronic acid 4 mg IV every 
three months or placebo. At one year, the placebo group 
lost 2%–3% BMD at the lumbar spine, femoral neck, and 
total hip. By comparison, treated group had gains in BMD 
and showed significantly greater BMD at each skeletal site 
(see Table 3).
Michaelson and colleagues88 randomized 40 men with 
nonmetastatic prostate cancer on ADT and osteoporosis (T 
 -2.5), to receive a single dose 4 mg IV zoledronic acid or 
placebo. Subjects who received zoledronic acid had significant 
reductions in N-telopeptide and bone-specific alkaline phos-
phatase at 12 months as well as significantly greater BMD at 
the lumbar spine, total hip and femoral neck (see Table 3).
Ryan and colleagues89 studied 42 men with hormone-
sensitive prostate cancer with and without metastasis on 
ADT less than one year. The subjects were randomized to 
zoledronic acid 4 mg IV every three months or placebo. 
Skeletal sites with metastasis were excluded from DEXA 
measurement of BMD. At 12 months, subjects treated 
with zoledronic acid had significantly greater decreases 
in N-telopeptide and bone-specific alkaline phosphatase. 
Men with bone metastases had significantly higher baseline 
N-telopeptide and bone-specific alkaline phosphatase, but 
the improvements in suppression of these markers of bone 
turnover was independent of the presence of metastases. 
Treated subjects also had significantly greater BMD at the 
lumbar spine and femoral neck (see Table 3).
raloxifene in ADT
Estrogen deficiency plays a significant role in bone loss 
in men. Doran and colleagues90 randomized 50 elderly 
men without osteoporosis to receive the selective estrogen 
receptor modulator (SERM) raloxifene 60 mg per day or 
placebo. At six months, the treated group overall showed no 
effect in decreasing urinary N-telopeptide (NTx) excretion. 
However, in the subset of men with baseline low estradiol 
levels (mean 22 pg/mL), raloxifene treatment decreased 
urinary NTx. Smith and colleagues91 found a similar treat-
ment effect in 48 men with nonmetastatic prostate cancer on 
GnRH agonist therapy treated with raloxifene 60 mg daily. 
The average estradiol level was 5 pg/mL. At 12 months, the 
raloxifene-treated group had significantly decreased serum 
amino-terminal propeptide of type I collagen and significantly 
increased BMD in the total hip (+1.1% vs -2.6%, p  0.001) 
and a nonsignificant trend to increased density in the lumbar 
spine (+1.0% vs -1.0%, p = 0.07).
Raloxifene is not approved in the US for the treatment 
of osteoporosis in men.
Indications
Zoledronic acid (Reclast) is approved in the US as an annual 
IV infusion of 5 mg to treat osteoporosis in men or women 
and to treat Paget’s disease. Zoledronic acid is also marketed 
as a 4 mg dose (Zometa®) IV infusion every 3–4 weeks to 
treat hypercalcemia of malignancy, multiple myeloma, and 
bone metastases from all solid tumors including lung and 
prostate cancer.
Zoledronic acid is the only IV bisphosphonate approved 
in the US for the treatment of osteoporosis in men.
Adverse drug effects
Eight trials of zoledronic acid including men for nonmetastatic 
bone loss have been published,69,72,75,79,86–89 and all eight 
reported basic safety data such as number of subjects who 
died or withdrew because of adverse events. Six of these 
studies69,72,75,86,87,89 reported more extensive safety analyses. 
In the largest of these trials,69 there was no association 
between zoledronic acid and early study withdrawal due to 
adverse event.
Prior studies92 have identified five typical infusion-related 
symptoms that occur in more than 30% subjects receiving a 
first dose zoledronic acid within three days of drug admin-
istration. These symptoms include myalgias, influenza-like 
symptoms, fever, arthralgias, and headache. The reported 
rates of these symptoms in the eight trials described are 
generally lower than in prior studies, though myalgias and 
fever were significantly more common in the zoledronic 
acid-treated subjects.69 These symptoms are typically mild, 
resolve within 3–4 days, and occur less frequently with Clinical Interventions in Aging 2009:4 300
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successive infusions of the drug. Patients should be pretreated 
with acetominophen.
Many symptoms were variably described among the stud-
ies. The frequency of a composite of reports of bone or back 
pain, myalgias, and arthralgias was 9% among zoledronic 
acid-treated subjects vs 5% among those receiving placebo. 
Currently the US FDA is investigating reports of “severe and 
sometimes incapacitating bone, joint, and/or muscle pains” 
in chronic use of bisphosphonates as a class.93
Infusing zoledronic acid over at least 15 minutes reduces 
the risk of renal toxicity. In each of the studies cited, zoledronic 
acid was given over 15 minutes, and there was no significant 
difference in rates of rise of serum creatinine 0.5 mg/dL.69,72 
Zoledronic acid 5 mg dose (Reclast®) is not recommended for 
patients with creatinine clearance 35 mL/min due to lack of 
experience in this patient population. Zoledronic acid 4 mg 
(Zometa®) is recommended at full dose for patients with esti-
mated creatinine clearance 60 mL/min with dose reductions 
for creatinine clearances between 30–60 mL/min. Because 
of the lack of clinical data to date, it is not recommended 
for use in patients with creatinine clearance 30 mL/min. 
Asymptomatic and generally transient hypocalcemia and 
hypophosphatemia have been reported independent of base-
line 25-OH vitamin D levels.72
Osteonecrosis of the jaw (ONJ) is a serious complication 
of bisphosphonate use defined as an area of exposed bone in 
the maxillofacial region that does not heal within eight weeks 
after identification by a health care provider.94 It appears that 
potency of the bisphosphonate and duration of exposure to the 
drug increase the risk of ONJ. Patient factors which increase 
the risk of ONJ include cancer diagnosis, chemotherapy, 
glucocorticoid use, tobacco use, and pre-existing dental and 
periodontal disease. Although the true incidence of ONJ is 
unknown, recent expert consensus94 estimates 1/10,000 to 
less than 1/100,000 patient-years in patients receiving oral 
bisphosphonate treatment for osteoporosis.
In the above eight zoledronic acid trials including 2563 
subjects studied over 6960 patient-years, not a single case 
of ONJ was reported. However, these numbers must be 
interpreted with caution in that cumulative exposure and 
duration of follow-up (average 1–2 years) may not be 
enough to detect ONJ. The incidence of ONJ in patients 
receiving IV zoledronic acid for treatment of malignancy 
is much higher, as high as 1%–10%.94 Boonyapakorn and 
colleagues95 prospectively studied 80 patients receiving 
monthly IV zoledronic acid or pamidronate for cancer diag-
nosis, most commonly multiple myeloma and breast cancer. 
Using dental radiographs and intraoral examinations, they 
found that 22 (28%) patients developed ONJ after bisphos-
phonate exposure. The mean time from exposure to ONJ in 
the zoledronic acid-treated patients was 26 months. Initiation 
of bisphosphonate therapy need not be delayed for routine 
dental work, but patients should be counseled on the impor-
tance of dental hygiene and recommended to have regular 
dental visits for routine care.
Black and colleagues92 reported an increased incidence 
of serious atrial fibrillation in women treated with zoledronic 
acid infusion, and Heckbert and colleagues96 found greater 
likelihood of prior alendronate use among 719 women with 
confirmed new onset atrial fibrillation. In contrast, Lyles 
and colleagues69 found no association between zoledronic 
acid and atrial fibrillation, stroke, myocardial infarction, or 
death from cardiovascular causes. Sørensen and colleagues97 
retrospectively studied 13,586 Danish women with atrial 
fibrillation and atrial flutter and found that alendronate and 
etidronate use was not more common among affected patients 
than population controls (adjusted relative risk among women 
with current bisphosphonate use 0.95). US FDA review of 
19,687 bisphosphonate-treated patients found no association 
with atrial fibrillation.98 Whether bisphosphonate use predis-
poses a patient to atrial fibrillation remains an open ques-
tion. However, this small potential risk must be considered 
in relation to potentially large benefits in terms of fracture 
reduction and survival.
Summary
Osteoporosis and low bone mass are under-recognized 
and undertreated in men. As the population ages, the rates 
of osteoporosis and osteoporotic fractures are expected to 
rise. Men with prior fragility fractures, older men, and men 
with lower BMD are at highest risk of fracture. Men with 
glucocorticoid use, hypogonadism, tobacco or heavy alco-
hol intake, vitamin D deficiency, or androgen deprivation 
therapy for prostate cancer are also at increased risk for 
osteoporosis. Laboratory evaluation for secondary causes of 
osteoporosis and radiographic screening for occult vertebral 
fractures in men with height loss are essential parts of the 
workup of men with osteoporosis. All men should receive 
adequate dietary calcium and vitamin D. Bisphosphonates 
are potent antiresorptive agents that inhibit osteoclast 
activity, suppress in vivo markers of bone turnover, and 
decrease fracture risk in patients at high risk of fracture. 
Intravenous zoledronic acid may be a preferable alternative 
to oral bisphosphonate therapy in patients with cognitive 
dysfunction, the inability to sit upright, or significant gas-
trointestinal pathology.Clinical Interventions in Aging 2009:4 301
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